Fluphenazine (oral) versus atypical antipsychotics for schizophrenia

  • Protocol
  • Intervention

Authors

  • James Sampford,

    Corresponding author
    1. Leeds and York Partnership NHS Foundation Trust, Liaison Psychiatry, Leeds, UK
    • James Sampford, Liaison Psychiatry, Leeds and York Partnership NHS Foundation Trust, Rose Garden Offices, Brotherton Wing,, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK. james.sampford@nhs.net.

    Search for more papers by this author
  • Stephanie Sampson

    1. The University of Nottingham, Cochrane Schizophrenia Group, Nottingham, UK
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To measure the outcomes (both beneficial and harmful) of the clinical effectiveness, safety and cost effectiveness of oral fluphenazine versus atypical antipsychotics for schizophrenia.